Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock
February 11 2014 - 8:00AM
Marketwired
Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred
Stock
TUSTIN, CA--(Marketwired - Feb 11, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) (the "Company"), announced
today that it has priced an underwritten public offering of 700,000
shares of its 10.50% Series E Convertible Preferred Stock (the
"Series E Preferred Stock") at a public offering price of $25.00
per share. Holders of Series E Preferred Stock may convert
their shares, in whole or in part, into shares of the Company's
common stock at a conversion price of $3.00 per share. Gross
proceeds to the Company are expected to be approximately $17.5
million ($20.1 million if the option described below is exercised
in full) before deducting the underwriting discount and other
estimated offering expenses payable by the Company. The
offering is expected to close on or about February 19, 2014,
subject to the satisfaction of customary closing
conditions. The Company has also granted the underwriters an
option to purchase up to an aggregate of 105,000 additional shares
of its Series E Preferred Stock offered in the public offering,
exercisable for 30 days. The Company intends to use the net
proceeds from the offering for general corporate purposes. The
Company has filed an application to list the shares of Series E
Preferred Stock on the NASDAQ Capital Market under the symbol
"PPHMP". If approved by NASDAQ, trading of the Series E
Preferred Stock on the NASDAQ is expected to begin within 30 days
after the date of initial issuance of the Series E Preferred
Stock. MLV & Co. LLC is acting as sole
book-runner. Maxim Group LLC and National Securities
Corporation, a wholly owned subsidiary of National Holdings, Inc.
(OTCBB: NHLD), are acting as lead managers for the offering and
Empire Asset Management and I-Bankers Securities, Inc. are acting
as co-managers for the offering. Roth Capital Partners, LLC
and Piper Jaffray & Co. served as financial advisors to
Peregrine.
The offering is being made pursuant to the Company's existing
effective shelf registration statement, previously filed with the
Securities and Exchange Commission ("SEC"). A final prospectus
supplement related to the offering will be filed with the SEC and
will be available on the SEC's website located at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may be
obtained by contacting:
MLV & Co. LLC 1251 Avenue of the Americas, New York, NY
10020 Attention: Randy Billhardt, email: rbillhardt@mlvco.com
Telephone: (212) 542-5882
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment
and diagnosis of cancer. The Company is pursuing multiple clinical
programs in cancer with its lead immunotherapy candidate
bavituximab while seeking a partner to further advance its novel
brain cancer agent Cotara®. Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found
at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release
which are not purely historical, including statements regarding
Peregrine Pharmaceuticals' intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The
forward-looking statements involve risks and uncertainties
including, but not limited to, the risk that enrollment of the
Phase III trial may experience delays or take longer than
anticipated, the risk that the results from the Phase III trial may
not support a future Biologics License Application (BLA)
submission, the risk that the Company may not have or raise
adequate financial resources to complete the Phase III trial and
the risk that the Company may not find a suitable partner for the
Phase III trial or the PS program. It is important to note that the
Company's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to,
uncertainties associated with completing preclinical and clinical
trials for our technologies; the early stage of product
development; the significant costs to develop our products as all
of our products are currently in development, preclinical studies
or clinical trials; obtaining additional financing to support our
operations and the development of our products; obtaining
regulatory approval for our technologies; anticipated timing of
regulatory filings and the potential success in gaining regulatory
approval and complying with governmental regulations applicable to
our business. Our business could be affected by a number of other
factors, including the risk factors listed from time to time in our
reports filed with the SEC including, but not limited to, our
annual report on Form 10-K for the fiscal year ended April 30, 2013
and quarterly report on Form 10-Q for the quarter ended October 31,
2013. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release.
Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does
not undertake to update or revise any forward-looking statements in
this press release.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024